254 related articles for article (PubMed ID: 29393340)
41. Tumor development, growth characteristics and spectrum of genetic aberrations in the TH-MYCN mouse model of neuroblastoma.
Rasmuson A; Segerström L; Nethander M; Finnman J; Elfman LH; Javanmardi N; Nilsson S; Johnsen JI; Martinsson T; Kogner P
PLoS One; 2012; 7(12):e51297. PubMed ID: 23284678
[TBL] [Abstract][Full Text] [Related]
42. The p53 pathway and its inactivation in neuroblastoma.
Tweddle DA; Pearson AD; Haber M; Norris MD; Xue C; Flemming C; Lunec J
Cancer Lett; 2003 Jul; 197(1-2):93-8. PubMed ID: 12880966
[TBL] [Abstract][Full Text] [Related]
43. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells.
Endo S; Yamato K; Hirai S; Moriwaki T; Fukuda K; Suzuki H; Abei M; Nakagawa I; Hyodo I
Cancer Sci; 2011 Mar; 102(3):605-13. PubMed ID: 21205074
[TBL] [Abstract][Full Text] [Related]
44. p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy.
Moreno-Smith M; Lakoma A; Chen Z; Tao L; Scorsone KA; Schild L; Aviles-Padilla K; Nikzad R; Zhang Y; Chakraborty R; Molenaar JJ; Vasudevan SA; Sheehan V; Kim ES; Paust S; Shohet JM; Barbieri E
Clin Cancer Res; 2017 Nov; 23(21):6629-6639. PubMed ID: 28821555
[No Abstract] [Full Text] [Related]
45. TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation.
Drummond CJ; Esfandiari A; Liu J; Lu X; Hutton C; Jackson J; Bennaceur K; Xu Q; Makimanejavali AR; Del Bello F; Piergentili A; Newell DR; Hardcastle IR; Griffin RJ; Lunec J
Oncotarget; 2016 Jul; 7(29):46203-46218. PubMed ID: 27323823
[TBL] [Abstract][Full Text] [Related]
46. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma.
Slack A; Chen Z; Tonelli R; Pule M; Hunt L; Pession A; Shohet JM
Proc Natl Acad Sci U S A; 2005 Jan; 102(3):731-6. PubMed ID: 15644444
[TBL] [Abstract][Full Text] [Related]
47. MDM2 but not MDM4 promotes retinoblastoma cell proliferation through p53-independent regulation of MYCN translation.
Qi DL; Cobrinik D
Oncogene; 2017 Mar; 36(13):1760-1769. PubMed ID: 27748758
[TBL] [Abstract][Full Text] [Related]
48. Cell lines from MYCN transgenic murine tumours reflect the molecular and biological characteristics of human neuroblastoma.
Cheng AJ; Cheng NC; Ford J; Smith J; Murray JE; Flemming C; Lastowska M; Jackson MS; Hackett CS; Weiss WA; Marshall GM; Kees UR; Norris MD; Haber M
Eur J Cancer; 2007 Jun; 43(9):1467-75. PubMed ID: 17449239
[TBL] [Abstract][Full Text] [Related]
49. The MDM2 antagonist nutlin-3 sensitizes p53-null neuroblastoma cells to doxorubicin via E2F1 and TAp73.
Peirce SK; Findley HW
Int J Oncol; 2009 May; 34(5):1395-402. PubMed ID: 19360352
[TBL] [Abstract][Full Text] [Related]
50. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells.
Miyachi M; Kakazu N; Yagyu S; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H
Clin Cancer Res; 2009 Jun; 15(12):4077-84. PubMed ID: 19509161
[TBL] [Abstract][Full Text] [Related]
51. Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen.
Michaelis M; Agha B; Rothweiler F; Löschmann N; Voges Y; Mittelbronn M; Starzetz T; Harter PN; Abhari BA; Fulda S; Westermann F; Riecken K; Spek S; Langer K; Wiese M; Dirks WG; Zehner R; Cinatl J; Wass MN; Cinatl J
Sci Rep; 2015 Feb; 5():8202. PubMed ID: 25644037
[TBL] [Abstract][Full Text] [Related]
52.
Yogev O; Almeida GS; Barker KT; George SL; Kwok C; Campbell J; Zarowiecki M; Kleftogiannis D; Smith LM; Hallsworth A; Berry P; Möcklinghoff T; Webber HT; Danielson LS; Buttery B; Calton EA; da Costa BM; Poon E; Jamin Y; Lise S; Veal GJ; Sebire N; Robinson SP; Anderson J; Chesler L
Cancer Res; 2019 Oct; 79(20):5382-5393. PubMed ID: 31405846
[TBL] [Abstract][Full Text] [Related]
53. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
Fang DD; Tang Q; Kong Y; Wang Q; Gu J; Fang X; Zou P; Rong T; Wang J; Yang D; Zhai Y
J Immunother Cancer; 2019 Nov; 7(1):327. PubMed ID: 31779710
[TBL] [Abstract][Full Text] [Related]
54. Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro.
Burmakin M; Shi Y; Hedström E; Kogner P; Selivanova G
Clin Cancer Res; 2013 Sep; 19(18):5092-103. PubMed ID: 23864164
[TBL] [Abstract][Full Text] [Related]
55. Spiro-oxindole derivative 5-chloro-4',5'-diphenyl-3'-(4-(2-(piperidin-1-yl) ethoxy) benzoyl) spiro[indoline-3,2'-pyrrolidin]-2-one triggers apoptosis in breast cancer cells via restoration of p53 function.
Saxena R; Gupta G; Manohar M; Debnath U; Popli P; Prabhakar YS; Konwar R; Kumar S; Kumar A; Dwivedi A
Int J Biochem Cell Biol; 2016 Jan; 70():105-17. PubMed ID: 26556313
[TBL] [Abstract][Full Text] [Related]
56. p53 cellular localization and function in neuroblastoma: evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells.
Tweddle DA; Malcolm AJ; Cole M; Pearson AD; Lunec J
Am J Pathol; 2001 Jun; 158(6):2067-77. PubMed ID: 11395384
[TBL] [Abstract][Full Text] [Related]
57. Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A.
Müller CR; Paulsen EB; Noordhuis P; Pedeutour F; Saeter G; Myklebost O
Int J Cancer; 2007 Jul; 121(1):199-205. PubMed ID: 17354236
[TBL] [Abstract][Full Text] [Related]
58. Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals.
Candido S; Abrams SL; Steelman LS; Lertpiriyapong K; Martelli AM; Cocco L; Ratti S; Follo MY; Murata RM; Rosalen PL; Bueno-Silva B; de Alencar SM; Lombardi P; Mao W; Montalto G; Cervello M; Rakus D; Gizak A; Lin HL; Libra M; Akula SM; McCubrey JA
Adv Biol Regul; 2019 May; 72():22-40. PubMed ID: 30898612
[TBL] [Abstract][Full Text] [Related]
59. An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals.
Mohammad RM; Wu J; Azmi AS; Aboukameel A; Sosin A; Wu S; Yang D; Wang S; Al-Katib AM
Mol Cancer; 2009 Dec; 8():115. PubMed ID: 19958544
[TBL] [Abstract][Full Text] [Related]
60. MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death.
Barbieri E; Mehta P; Chen Z; Zhang L; Slack A; Berg S; Shohet JM
Mol Cancer Ther; 2006 Sep; 5(9):2358-65. PubMed ID: 16985070
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
